ANTIVIRAL TECHNOLOGIES, INC.: 10-K filed 2014-03-28
What ANTIVIRAL TECHNOLOGIES, INC. reported in its annual report filed 2014-03-28 (fiscal FY 2013): 20 published measures, 47 facts as tagged in accession 0001137050-14-000058.
This filing
- Form
- 10-K (annual report)
- Filed
- 2014-03-28
- Fiscal period
- fiscal FY 2013
- Accession
- 0001137050-14-000058 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ANTIVIRAL TECHNOLOGIES, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 484,158 | USD | |
| At 2012-12-31 | 485,196 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 3,166,758 | USD | |
| At 2012-12-31 | 2,787,712 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | -2,682,600 | USD | |
| At 2012-12-31 | -2,302,516 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 499 | USD | |
| At 2012-12-31 | 699 | USD | |
| At 2011-12-31 | 3,935 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-12-31 | -375,946 | USD | 365 |
| 2007-09-13 to 2013-12-31 | -2,675,284 | USD | 2302 |
| 2012-01-01 to 2012-12-31 | -363,282 | USD | 366 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-12-31 | -87,519 | USD | 365 |
| 2007-09-13 to 2013-12-31 | -1,294,805 | USD | 2302 |
| 2012-01-01 to 2012-12-31 | -139,177 | USD | 366 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-12-31 | 127,752 | USD | 365 |
| 2007-09-13 to 2013-12-31 | 1,916,963 | USD | 2302 |
| 2012-01-01 to 2012-12-31 | 244,403 | USD | 366 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-12-31 | -36,398 | USD | 365 |
| 2007-09-13 to 2013-12-31 | -593,108 | USD | 2302 |
| 2012-01-01 to 2012-12-31 | -103,109 | USD | 366 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 642 | USD | |
| At 2012-12-31 | 1,603 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 501 | USD | |
| At 2012-12-31 | 701 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2007-09-13 to 2013-12-31 | -31,962 | USD | 2302 |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 483,015 | USD | |
| At 2012-12-31 | 482,892 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 150,000,000 | shares | |
| At 2012-12-31 | 150,000,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | -144,858 | USD | |
| At 2012-12-31 | -144,858 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | -12,458 | USD | |
| At 2012-12-31 | -8,320 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 11,029 | USD | |
| At 2012-12-31 | 10,836 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | -10,387 | USD | |
| At 2012-12-31 | -9,283 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-12-31 | -380,084 | USD | 365 |
| 2007-09-13 to 2013-12-31 | -2,687,742 | USD | 2302 |
| 2012-01-01 to 2012-12-31 | -368,721 | USD | 366 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-12-31 | 375,245 | USD | 365 |
| 2007-09-13 to 2013-12-31 | 2,503,636 | USD | 2302 |
| 2012-01-01 to 2012-12-31 | 356,438 | USD | 366 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-12-31 | 995 | USD | 365 |
| 2007-09-13 to 2013-12-31 | 10,128 | USD | 2302 |
| 2012-01-01 to 2012-12-31 | 1,305 | USD | 366 |
Inspect the source
- Entity
- ANTIVIRAL TECHNOLOGIES, INC. / CIK 0001445226
- Captured
- SEC response SHA-256
8eebaa08a3fdfe2277d78068fe27fc31b233085f2e48bbd10b68292209892301
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001445226.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))